Clinical trial
A Multi-center, Open-label Study to Assess the Long-term Safety of Droxidopa in Subjects With Primary Autonomic Failure, Dopamine Beta Hydroxylase Deficiency or Non-Diabetic Neuropathy and Symptomatic Neurogenic Orthostatic Hypotension
NCT01132326 is registered in ClinicalTrials.gov with Chelsea Therapeutics as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Multi-center, Open-label Study to Assess the Long-term Safety of Droxidopa in Subjects With Primary Autonomic Failure, Dopamine Beta Hydroxylase Deficiency or Non-Diabetic Neuropathy and Symptomatic Neurogenic Orthostatic Hypotension
- Lead sponsor
- Chelsea Therapeutics
- Phase
- Phase 3
- Overall status
- Completed
- Start date
- January 31, 2009
- Completion date
- February 28, 2013
- Enrollment
- 350 (actual)
- Sites
- Not reported
Conditions
As the registry lists them; a condition with its own page is linked.
dopamine beta hydroxylase deficiency, neurogenic orthostatic hypotension, non-diabetic neuropathy, primary autonomic failure